BioSpace News Archive

The global over-the-counter (OTC) analgesics market size was reached USD 28.6 billion in 2022 and is projected to surpass around USD 40.93 billion by 2032, expanding at a CAGR of 3.7% from 2023 to 2032.

The global antibodies drug market size reached USD 2,00,180 million in 2022 and is estimated to surpass around USD 6,05,800 million by 2032, growing at a CAGR of 10.8% between 2023 and 2032.

Davion Healthcare Plc, a leading medical device manufacturer, is pleased to announce that it has granted a Global Manufacturing and Distribution Licence for Davion’s non-invasive BreastCheck

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the third quarter of 2023 and recent corporate updates.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2023 financial results.

Tarsus Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023, and recent business achievements.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

Immuneering Corporation reported financial results for the third quarter ended September 30, 2023, and provided business updates.

Alpha Teknova, Inc., a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, announced financial results for the third quarter ended September 30, 2023.